BioSpace News Archive

Nightstar Therapeutics plc, announced that positive preliminary safety and efficacy data of NSR-RPGR from the dose escalation study in the Phase 1/2 XIRIUS trial were presented today at the EURETINA 2018 Congress.

Alzheimer’s Research UK, one of the top dementia research funders in the world, is calling on the UK government to adopt a bold new action plan to bring about a life-changing dementia treatment and improve the lives of people with the condition.

GeoVax Labs Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, today commented on recent age-associated HIV infection trends observed in the United States.

A new Philadelphia-based start-up, Virion Therapeutics, LLC spun out of The Wistar Institute, will work to advance innovative, immune-based therapies for the treatment of chronic viral-associated cancers and viral infections utilizing the first genetically encoded checkpoint inhibitor that can be given via vaccination.

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the Company will present at the Cantor Fitzgerald 2018 Global Healthcare Conference on Tuesday, October 2

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or “the Company”) today announced that the Compensation Committee of the Company’s Board of Directors has approved the appointment of David Pernock to the position of Chief Operating Officer, effective as of September 1, 2018.

Research shows adding Abbott’s High Sensitive Troponin-I diagnostic test to doctors’ existing standard of care can help more accurately determine a person’s chances of a heart attack or other cardiac event potentially months to years in advance

Sutro Biopharma, Inc. today announced the pricing of its initial public offering of 5,667,000 shares of its common stock at a price to the public of $15.00 per share.